Evidence map›Paper›PMID 24145241›Full record

ReviewMolecular aspects of medicine2014

Stem cells and targeted approaches to melanoma cure.

George F Murphy, Brian J Wilson, Sasha D Girouard, Natasha Y Frank, Markus H Frank

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular aspects of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. The mOncogene · 2022
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.Laboratory investigation; a journal of technical methods and pathology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

George F MurphyDepartment of Pathology, Brigham & Women's Hospital, Boston, MA, USA. Electronic address: gmurphy@rics.bwh.harvard.edu.
Brian J WilsonTransplantation Research Center, Children's Hospital Boston, Boston, MA, USA; Department of Dermatology, Brigham & Women's Hospital, Boston, MA, USA.
Sasha D GirouardDermatology Residency Program, Harvard Medical School, Boston, MA, USA.
Natasha Y FrankDepartment of Medicine, VA Boston Healthcare System, Boston, MA, USA.
Markus H FrankTransplantation Research Center, Children's Hospital Boston, Boston, MA, USA; Department of Dermatology, Brigham & Women's Hospital, Boston, MA, USA. Electronic address: markus.frank@childrens.harvard.edu.

Funding

Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities forP50CA093683 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KUPPER, THOMAS S. · 2001 to 2012
$25.8M
Immunology of human malignant melanoma initiating cellsR01CA158467 · NCI · BOSTON CHILDREN'S HOSPITAL · PI FRANK, MARKUS H., HODI, FRANK S · 2012 to 2016
$1.9M
Melanoma Stem Cells, Vasculogenesis and Neoplastic ProgressionR01CA138231 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI FRANK, MARKUS H. · 2008 to 2012
$1.7M
ABCB5 P-Glycoprotein in Cancer Multidrug ResistanceR01CA113796 · NCI · BOSTON CHILDREN'S HOSPITAL · PI FRANK, MARKUS H. · 2006 to 2010
$1.5M
Identification and targeting of colon cancer initiating cellsI01BX000516 · VA · VA BOSTON HEALTH CARE SYSTEM · PI FRANK, NATASHA Y · 2011 to 2020
–
ABCB5+ Dermal Stem Cells In Regenerative Wound HealingI01RX000989 · VA · VA BOSTON HEALTH CARE SYSTEM · PI FRANK, NATASHA Y · 2015 to 2017
–
BLRD VA I01 BX000516NCI NIH HHS P50 CA093683NCI NIH HHS P50CA093683NCI NIH HHS R01 CA113796NCI NIH HHS R01CA113796NCI NIH HHS R01 CA138231NCI NIH HHS R01CA138231NCI NIH HHS R01 CA158467NCI NIH HHS R01CA158467RRD VA I01 RX000989
6 · The paper itself

Abstract

Melanoma stem cells, also known as malignant melanoma-initiating cells, are identifiable through expression of specific biomarkers such as ABCB5 (ATP-binding cassette, sub-family B (MDR/TAP), member 5), NGFR (nerve growth factor receptor, CD271) and ALDH (aldehyde dehydrogenase), and drive melanoma initiation and progression based on prolonged self-renewal capacity, vasculogenic differentiation and immune evasion. As we will review here, specific roles of these aggressive subpopulations have been documented in tumorigenic growth, metastatic dissemination, therapeutic resistance, and malignant recurrence. Moreover, recent findings have provided pre-clinical proof-of-concept for the potential therapeutic utility of the melanoma stem cell concept. Therefore, melanoma stem cell-directed therapeutic approaches represent promising novel strategies to improve therapy of this arguably most virulent human cancer.

Indexed as

AnimalsDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionHumansMelanomaMolecular Targeted TherapyNeoplastic Stem CellsABCB5Cancer stem cellDrug resistanceImmune evasionMelanomaTherapyVasculogenic mimicry

Identifiers

PMID24145241
PMCPMC3992197

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.